	US 12,377,076 B2
	Compounds for treating lymphoma or a T-cell malignant disease
Katarina Hilgier, Zurich (CH); Francisco Ibanez Lopez, Alicante (ES); and Thomas Jorg Mehrling, Riehen (CH)
Assigned to Purdue Pharma L.P., Stamford, CT (US)
Appl. No. 17/414,797
Filed by Purdue Pharma L.P., Stamford, CT (US)
PCT Filed Dec. 18, 2019, PCT No. PCT/IB2019/061034 § 371(c)(1), (2) Date Jun. 16, 2021, PCT Pub. No. WO2020/128912, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 1820643 (GB), filed on Dec. 18, 2018; application No. 1820645 (GB), filed on Dec. 18, 2018; application No. 1903003 (GB), filed on Mar. 6, 2019; application No. 1903005 (GB), filed on Mar. 6, 2019; application No. 1908434 (GB), filed on Jun. 12, 2019; and application No. 1908436 (GB), filed on Jun. 12, 2019.
Prior Publication US 2022/0016084 A1, Jan. 20, 2022
Int. Cl. A61K 31/4184 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61P 7/00 (2006.01); A61P 35/00 (2006.01); G16H 20/10 (2018.01)

CPC A61K 31/4184 (2013.01) [A61K 9/0019 (2013.01); A61K 45/06 (2013.01); A61P 7/00 (2018.01); A61P 35/00 (2018.01); G16H 20/10 (2018.01)]

18 Claims

1. A method of treating lymphoma or a T-cell malignant disease in a patient having said lymphoma or said T-cell malignant disease, said method comprising administering to the patient an amount of tinostamustine or a pharmaceutically acceptable salt thereof, wherein the amount is:

(i) if the patient's initial platelet count is equal to or above 200×10⁹/L, a first amount of tinostamustine or pharmaceutically acceptable salt thereof of 95 mg/m²or greater, based on free tinostamustine and the patient's body surface area; and

(ii) if the patient's initial platelet count is equal to or below 100×10⁹/L, a second amount of tinostamustine or pharmaceutically acceptable salt thereof of 54 mg/m²or lower; and

(iii) if the patient's initial platelet count is between 100×10⁹/L and 200×10⁹/L, a third amount of tinostamustine or pharmaceutically acceptable salt thereof of 75-85 mg/m²is administered.